Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to $74.3 million.

  • Barinthus Biotherapeutics' Cash & Equivalents fell 2999.94% to $74.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.3 million, marking a year-over-year decrease of 2999.94%. This contributed to the annual value of $110.7 million for FY2024, which is 2211.84% down from last year.
  • Per Barinthus Biotherapeutics' latest filing, its Cash & Equivalents stood at $74.3 million for Q3 2025, which was down 2999.94% from $86.3 million recorded in Q2 2025.
  • In the past 5 years, Barinthus Biotherapeutics' Cash & Equivalents registered a high of $243.6 million during Q2 2021, and its lowest value of $74.3 million during Q3 2025.
  • Its 5-year average for Cash & Equivalents is $159.3 million, with a median of $160.3 million in 2023.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 39473.95% in 2021, then tumbled by 3381.41% in 2024.
  • Quarter analysis of 5 years shows Barinthus Biotherapeutics' Cash & Equivalents stood at $214.1 million in 2021, then fell by 9.19% to $194.4 million in 2022, then dropped by 26.9% to $142.1 million in 2023, then fell by 22.12% to $110.7 million in 2024, then plummeted by 32.88% to $74.3 million in 2025.
  • Its last three reported values are $74.3 million in Q3 2025, $86.3 million for Q2 2025, and $99.1 million during Q1 2025.